HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by , Search for Related Content PubMed PubMed Citation Articles by , Related Collections San Diego Conference

Poster Session Abstracts

WITHDRAWN

2

Development, Optimization, and Scale-up of a Chromatographic Purification of a Synthetic Oligonucleotide. Fisher, J.; O'Donnell, J.; Rosen, R.; Maikner, J.; Kraus, M.; Juliano, S. Picciotti; TosoHaas, Montgomeryville, PA. Rohm and Haas Company, Spring House, PA, TosoHaas GMBH, Stuttgart, Germany

The objective of this study was to develop and scale-up a chromatographic purification process for a crude, synthetic, DMT-on, phosphodiester oligonucleotide. A separation process was developed on a 1.0cm I.D. x 6.2cm L, lab-scale column, using an experimental 15µm, polymeric reversed phase resin with a triethyl ammonium acetate/acetonitrile mobile phase. The experimental resin was styrene/divinylbenzene with an average pore diameter of 300 angstroms. The process was then scaled to 5cm I.D. x 10cm L, pilot-scale column using a commercially available 35µm polymeric reversed phase resin with similar mobile phase conditions. The process effectively combined removal of failure sequences, detritylation on-column, and elution of a high-purity oligonucleotide. The process was able to deliver purity levels >95% with yields >50% at both laboratory- and pilot-scale. This work was significant because it demonstrated that larger quantities of oligonucleotides can be successfully purified in a one-step chromatographic process for therapeutic purposes.

3

Automation of Extracellular Virus Detection Using Microporous Materials for Blood Separation. Alter, J.; Pall Corporation, Port Washington, NY, USA.

Currently, many automated clinical analyzers utilize serum as the starting sample for detection of analytes or viruses. Serum separation from whole blood requires centrifugation, which is not easily automated. In addition, extra steps, resources, personnel and an extended chain of custody are involved.

Future molecular assays should employ methods that allow whole blood to be assayed without the need for centrifugation. One approach is to utilize a solid support that separates plasma from whole blood in a single step. Separated plasma can then be transferred to a secondary solid support . . . [Full Text of this Article]

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49